{"prompt": "['OSTPDL1', 'Page 4 of 60', 'response rates seen in patients whose tumors had negative PD-L1', 'expression and were treated with single agent nivolumab, 24 suggesting', 'that PD-L1 might not be an optimal surrogate biomarker of response to', 'these agents. In addition, it is likely that inducible PD-L1 expression', 'appears to be more stringently correlated with PD-1 blockade response', 'as a result of adaptive immune resistance. 25 More recently, tumor specific', 'non-synonymous mutations have been identified as being immunogenic;', 'the majority of this \"mutanome\" is recognized by CD4+ T cells. To this', 'effect, increased mutational burden in melanoma has been associated', 'with responses to CTLA-4 blockade; however, increased mutational load', 'alone may not explain the benefit seen in these patients. The presence of', 'specific unique neoepitope signatures that confer higher rates of MHC I', 'class binding appears to be essential for achievement of clinical', 'response. 26,27 The dramatic response to checkpoint inhibitors in patients', 'with mutations in mismatch repair deficient colorectal cancer supports', 'the observation that a high mutational load is associated with the number', 'of mutation-associated antigens that can trigger an immune response', 'against the tumor.', '19', 'The high mutational load in osteosarcoma makes this tumor an attractive', 'target for immunotherapy. Recent work has demonstrated that human', 'metastatic osteosarcoma cells express PD-L1; populations of PD-L1', 'positive cells were observed in 12 of 16 metastatic tumors by', 'immunofluorescence. The presence of PD-L1 may decrease the activity of', 'cytotoxic T lymphocytes (CTLs) expressing PD-1; blockade of PD-1/PD-', 'L1 improved CTL function in vitro and in vivo. In a K7M2 mouse model of', 'osteosarcoma this resulted in decreased tumor burden and prolonged', 'survival. 28 In addition, in an implantable model of metastatic', 'osteosarcoma, T cells infiltrating PD-L1 antibody-resistant tumors up-', 'regulate additional inhibitory receptors, notably CTLA-4, which impairs', 'their ability to mediate tumor rejection. Combinations of a-CTLA-4 and', 'a-PD-L1 antibody blockade in the K7M2 mouse model of metastatic', 'osteosarcoma produces complete control of tumors in a majority of mice', 'as well as immunity to further tumor inoculation.29 In another study an', 'RNA-based assay to determine PDL1 expression levels showed 32 of 38', 'osteosarcoma tumors expressed PDL1; high levels (3 log or more) of', 'PDL1 were expressed in 9 tumor samples. PDL1 expression was positively', 'correlated with tumor infiltrating lymphocytes (TILs).30 While data is', 'limited on the clinical activity of PD-1 or PD-L1 inhibition in patients with', 'osteosarcoma, a recent report from a clinical trial utilizing the Merk PD-', '1 inhibitor pembrolizumab in patients with advanced bone and soft tissue', 'sarcomas demonstrated a partial response in 1 of 19 enrolled', 'osteosarcoma subjects at 8 weeks; limited data on progression free', 'survival was available.31', '2.2', 'Preclinical Studies', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']['OSTPDL1', 'Page 5 of 60', '2.2.1 Avelumab', 'Avelumab (also referred to as MSB0010718C) is a fully human IgG-1', 'antibody which is directed against PD-L1. Avelumab binds PD-L1 and', 'blocks the interaction between PD-L1 and its receptors PD-1 and B7-1.', 'The interaction between PD-L1 and PD-1/B7-1 significantly inhibits', 'activity of T cells. While PD-L1 can be detected on resting and activated T', 'cells, B cells, macrophages, dendritic cells and mast cells, tumor cells', 'may also express high levels of PD-L1 on their surface compared with', 'normal tissues. 32 High levels of PD-L1 expression have been found to be', 'associated with disease progression, increased metastasis, poor response', 'to treatment, and decreased survival in a number of human cancers.33', 'Blockade of PD-L1 removes the suppressive effects of PD-L1 on anti-', 'tumor CD8+ T cells, resulting in the restoration of cytotoxic T cell', 'response and elimination of tumor cells. Furthermore, as a fully human', 'IgG1 monoclonal antibody, avelumab has the potential to facilitate tumor', 'cell killing via tumor-directed antibody driven cellular cytotoxicity', '(ADCC).', '2.2.2 Preclinical Pharmacology Studies', 'Avelumab functionally enhances T cell activation in vitro and significantly', 'inhibits the growth of PD-L1 expressing tumors in vivo. Avelumab binds', 'to human PD-L1 with a high affinity of 0.7 nM and competitively blocks', 'the interaction of PD-L1 with PD-1. In vitro study results showed that by', 'binding to PD-L1, avelumab effectively enhances T cell activation as', 'measured by interleukin-2 (IL-2) or interferon-gamma (IFN-y)', 'production. As a monotherapy, avelumab demonstrated anti-tumor', 'activity against murine MC38 colon carcinoma tumors characterized by', 'high level of PD-L1 expression with an observed dose-dependent trend', 'when given every third day for a total of 3 doses. Dosing was determined', 'to be 400 g, approximating to 20 mg/kg. In vivo anti-tumor effects', 'were primarily mediated by CD8+ T cells as evidenced by observation', 'that in vivo depletion of CD8+ T cells abrogated anti-tumor efficacy. The', 'contribution of ADCC as a mechanism of anti-tumor activity was', 'demonstrated via use of a deglycosylated version of avelumab to', 'abrogate Fc receptor binding, and via systemic depletion of natural killer', '(NK) cells. In both settings, loss of in vivo ADCC potential significantly', 'reduced anti-tumor activity.', 'The combination of avelumab with commonly used cancer treatments,', 'such as cytotoxic agents and radiation therapy, resulted in improved', 'anti-tumor activity. The most promising combination partners for', 'avelumab were gemcitabine or 5-fluorouracil and oxaliplatin, the core', 'components of FOLFOX. Radiation therapy was found to be highly', 'synergistic with avelumab, capable of causing complete regression of', 'established tumors.', 'St. Jude', 'IRB NUMBER: Pro00006856', 'Revision 1.1, dated: 01-19-2018', 'IRB approved: APPROVAL DATE: 06/26/2019', 'Protocol document dated: 01-19-2018']\n\n###\n\n", "completion": "END"}